Clinical trials: Apixaban
Vaso-occlusive Crisis, Reduction in Hospitalizations
Apixaban in Patients With Sickle Cell Disease
In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a significant decrease in morbidity and as a result, decrease healthcare utilization and costs.
- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Trial name
- NCT02179177
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nirmish Shah
Atrial Fibrillation
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.
- Trial name
- NCT00787150
- Testing
- Apixaban, Warfarin sodium
- Where
- 18 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Pfizer
Healthy Volunteers
Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.
- Trial name
- NCT02034565
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Covid19
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
- Trial name
- NCT04650087
- Testing
- Apixaban 2.5 MG
- Where
- 121 sites in United States
- Volunteers
- 1,291 people
- Sponsor
- Thomas L. Ortel
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
- Trial name
- NCT03594045
- Testing
- Apixaban
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified.
- Conditions
- Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism
- Trial name
- NCT02889562
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sanford Health
Heart Failure
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin.
- Trial name
- DOAC LVAD (NCT04865978)
- Testing
- Apixaban, Warfarin, LVAD implant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palak Shah
Venous Thromboembolism, Multiple Myeloma
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs).
- Trial name
- NCT02958969
- Testing
- Apixaban
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gregory Piazza
Acute DVT of Lower Extremity
Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)
The Researchers are studying whether a vascular boot warming program plus standard of care anticoagulation can be a safe and effective method to resolve Deep Vein Thrombosis (DVT) ±Pulmonary Embolism (PE) earlier and prevent…
- Trial name
- NCT03465735
- Testing
- Vascular Boot, Standard of Care
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Atrial Fibrillation
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart.
- Trial name
- EMANATE (NCT02100228)
- Testing
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Where
- 165 sites in United States, Belgium and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Pfizer
Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).
- Trial name
- OCEANIC-AF (NCT05643573)
- Testing
- Asundexian (BAY2433334), Apixaban
- Where
- 1,069 sites in United States, Argentina and 36 more
- Volunteers
- 14,830 people
- Sponsor
- Bayer
Healthy
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily…
- Trial name
- NCT04593784
- Testing
- Ciraparantag, Point-of-Care Coagulometer (investigational device)
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Bariatric Surgery, Obesity
Apixaban Pharmacokinetics in Bariatric Patients (APB)
The Center for Bariatric Surgery is interested in conducting a pharmacokinetic study of apixaban (an oral anticoagulant with FDA approval for use of venous thrombo embolism (VTE) prophylaxis and treatment) in the obese adult…
- Trial name
- APB (NCT02406885)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Venous Thromboembolism
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
This study is a retrospective, observational, nationwide population-based cohort study utilizing the South Korea's Health Insurance and Review Assessment Service (HIRA) database.
- Trial name
- NCT05022563
- Testing
- Parenteral anticoagulant, Warfarin, Apixaban
- Where
- 2 sites in South Korea
- Volunteers
- 55,759 people
- Sponsor
- Pfizer
Healthy
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood…
- Trial name
- NCT03288454
- Testing
- Ciraparantag, Apixaban
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Thromboembolism
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin.
- Trial name
- NCT05643885
- Where
- United States
- Volunteers
- 7,304 people
- Sponsor
- Pfizer
Atrial Fibrillation
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
To describe the direct costs related to warfarin/apixaban treatment
- Trial name
- NCT04435769
- Where
- Czechia
- Volunteers
- 109 people
- Sponsor
- Pfizer
Acute Coronary Syndrome
Phase III Acute Coronary Syndrome
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
- Trial name
- APPRAISE-2 (NCT00831441)
- Testing
- Apixaban
- Where
- 1,012 sites in United States, Argentina and 38 more
- Volunteers
- 7,484 people
- Sponsor
- Bristol-Myers Squibb
Hemorrhage, Surgical, Hemorrhage Postoperative
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
- Conditions
- Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
- Trial name
- STAR-D (NCT05093504)
- Testing
- DrugSorb-ATR system
- Where
- 27 sites in United States
- Volunteers
- 9 people
- Sponsor
- CytoSorbents, Inc
Healthy Volunteers
Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy…
- Trial name
- NCT02034578
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb